Monitoring drug self-aggregation and potential for promiscuity in off-target in vitro pharmacology screens by a practical nmr strategy

Journal of Medicinal Chemistry

Volumn 56, Issue 17, 2013, Pages 7073-7083

  LaPlante, Steven R ^a   Aubry, Norman ^a   Bolger, Gordon ^a   Bonneau, Pierre ^a   Carson, Rebekah ^a   Coulombe, René ^a   Sturino, Claudio ^a   Beaulieu, Pierre L ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

POLYMER;

ARTICLE; CONTROLLED STUDY; DRUG MONITORING; IN VITRO STUDY; LIPOPHILICITY; MOLECULAR SIZE; PHYSICAL CHEMISTRY; PROTON NUCLEAR MAGNETIC RESONANCE;

MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR PROBES;

EID: 84884244385     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4008714     Document Type: Article

References (49)

1. Price, A. P.; Blagg, J.; Jones, L.; Greene, N.; Wager, T. Physicochemical drug properties associated with in vivo toxicological outcomes: a review Expert Opin. Drug Metab. Toxicol. 2009, 5, 921-931
2. Kola, I.; Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discovery 2004, 3, 711-715
3. Blagg, J. Structure-activity relationships for in vitro and in vivo toxicity Annu. Rep. Med. Chem. 2006, 41, 353-368
4. Kramer, J. A.; Sagartz, J. E.; Morris, D. L. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates Nat. Rev. Drug Discovery 2007, 6, 636-649
5. Azzaoui, K.; Hamon, J.; Faller, B.; Whitebread, S.; Jacoby, E.; Bender, A.; Jenkins, J. L.; Urban, L. Modeling promiscuity based on in vivo safety pharmacology profiling data ChemMedChem 2007, 2, 874-880
6. Stevens, J. L.; Baker, T. K. The future of drug safety testing: expanding the view and narrowing the focus Drug Discovery Today 2009, 14, 162-167
7. Krejsa, C. M.; Horvath, D.; Rogalski, S. L.; Penzotti, J. E.; Mao, B.; Barbosa, F.; Migeon, J. C. Predicting ADME properties and side effects: The BioPrint approach Curr. Opin. Drug Discovery Dev. 2003, 6, 470-480
8. Cronin, M. T. D. The role of hydrophobicity in toxicity prediction Curr.Comput.-Aided Drug Des. 2006, 2, 405-413
9. Cronin, M. T. D.; Livingstone, D. J. Predicting Chemical Toxicity and Fate; CRC Press: Boca Raton, FL, 2004; pp 391-412.
10. Kalgutkar, A. S.; Fate, G.; Didiuk, M. T.; Bauman, J. Toxicophores, reactive metabolites and drug safety: when is it a cause for concern? Expert Rev. Clin. Pharmacol. 2008, 1, 515-531
11. Hop, C. E. C.; Kalgutkar, A. S.; Soglia, J. R. Importance of early assessment of bioactivation in drug discovery Annu. Rep. Med. Chem. 2006, 41, 369-381
12. Williams, D. P.; Naisbitt, D. J. Toxicophores: groups and metabolic routes associated with increased safety risk Curr. Opin. Drug Discovery Dev. 2002, 5, 104-115
13. Bender, A.; Scheiber, J.; Glick, M.; Davies, J.; Azzaoui, K.; Hamon, J.; Urban, L.; Whitebread, S. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure ChemMedChem 2007, 2, 861-873
14. Dimova, D.; Hu, Y.; Bajorath, J. Matched Molecular Pair Analysis of Small Molecule Microarray Data Identifies Promiscuity Cliffs and Reveals Molecular Origins of Extreme Compound Promiscuity J. Med. Chem. 2012, 155, 10229-10228
15. Johnson, D. E.; Smith, D. A.; Park, K. B. Linking toxicity and chemistry: think globally, but act locally? Curr. Opin. Drug Discovery Dev. 2004, 7, 33-35
16. Alden, C. L. The pathologist and toxicologist in pharmaceutical product discovery Toxicol. Pathol. 1999, 27, 104-106
17. Cronin, M. T. D.; Zhao, Y. H.; Yu, R. L. pH-dependence and QSAR analysis of the toxicity of phenols and anilines to Daphnia magna Environ. Toxicol. 2000, 15, 140-148
18. Monks, T. J.; Jones, D. C. The metabolism and toxicity of quinones, quinonimines, quinone methides, and quinine-thioethers Curr. Drug Metab. 2002, 3, 425-438
19. Edwards, P. J.; Sturino, C. Managing the liabilities arising from structural alerts: a safe philosophy for medicinal chemists Curr. Med. Chem. 2011, 18, 3116-3135
20. Hughes, J. D.; Blagg, J.; Price, D. A.; Bailey, S.; DeCrescenzo, G. A.; Devraj, R. V.; Ellsworth, E.; Fobian, Y. M.; Gibbs, M. E.; Gilles, R. W.; Greene, N.; Huang, E.; Krieger-Burke, T.; Loesel, J.; Wager, T.; Whiteley, L.; Zhang, Y. Physicochemical drug properties associated with in vivo toxicological outcomes Bioorg. Med. Chem. Lett. 2008, 18, 4872-4875
21. Robichaud, A.; Savoie, C.; Stamatiou, P. B.; Lachance, N.; Jolicoeur, P.; Rasori, R.; Chan, C. C. Assessing the emetic potential of PDE4 inhibitors in rats Br. J. Pharmacol. 2002, 135, 113-118
22. Robichaud, A.; Savoie, C.; Stamatiou, P. B.; Tattersall, F. D.; Chan, C. C. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway Neuropharmacology 2001, 40, 262-269
23. Boswell-Smith, V.; Page, C. P. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory disease Expert Opin. Invest. Drugs 2006, 15, 1105-1113
24. Price, D. A.; Armour, D.; de Groot, M.; Leishman, D.; Napier, C.; Perros, M.; Stammen, B. L.; Wood, A. Overcoming hERG affinity in the discovery of maraviroc; a CCR5 antagonist for the treatment of HIV Curr. Top. Med. Chem. 2008, 13, 1140-1151
25. Singleton, D. H.; Price, D. A.; Deacon, M.; Boyd, H.; Steidl-Nichols, J. V.; Deacon, M.; de Groot, M. J.; Price, D.; Nettleton, D. O.; Wallace, N. K.; Troutman, M. D.; Williams, C.; Boyd, J. G. Fluorescently labelled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel J. Med. Chem. 2007, 50, 2931-2941
26. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890
27. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25
28. Lipinski, C. A. Lead- and drug-like compounds: the rule-of-five revolution Drug Discovery Today Technol. 2004, 1, 337-341
29. Wenlock, M. C.; Austin, R. P.; Barton, P.; Davis, A. M; Leeson, P. D. A comparison of physiochemical property profiles of development and marketed oral drugs J. Med. Chem. 2003, 46, 1250-1256
30. Vieth, M.; Siegel, M. G.; Higgs, R. E.; Watson, I. A.; Robertson, D. H.; Savin, K. A.; Durst, G. L.; Hipskind, P. A. Characteristic physical properties and structural fragments of marketed oral drugs J. Med. Chem. 2004, 47, 224-232
31. Proudfoot, J. R. The evolution of synthetic oral drug properties Bioorg. Med. Chem. Lett. 2005, 15, 1087-1090
32. Morphy, R. The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds J. Med. Chem. 2006, 49, 2969-2978
33. van de Waterbeemd, H.; Smith, D. A.; Beaumont, K.; Walker, D. K. Property-based design: optimization of drug absorption and pharmacokinetics J. Med. Chem. 2001, 44, 1313-1333
34. Cronin, M. T. D. The role of hydrophobicity in toxicity prediction Curr. Comp.-Aided Drug Des. 2006, 2, 405-413
35. Meanwell, N. A. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety Chem. Res. Toxicol. 2011, 24, 1420-1456
36. Tarcsay, A.; Keseru, G. M. Contribution of molecular properties to drug promiscuity J. Med. Chem. 2013, 56, 1789-1795
37. Seidler, J.; McGovern, S. L.; Doman, T. N.; Shoichet, B. K. Identification and prediction of promiscuous aggregating inhibitors among known drugs J. Med. Chem. 2003, 46, 4477-4486
38. McGovern, S. L.; Caselli, E.; Grigorieff, N.; Shoichet, B. K. A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening J. Med. Chem. 2002, 45, 1712-1722
39. Feng, B. Y.; Simeonov, A.; Jadhav, A.; Babaoglu, K.; Inglese, J.; Shoichet, B. K.; Austin, C. P. A High-Throughput Screen for Aggregation-Based Inhibition in a Large Compound Library J. Med. Chem. 2007, 50, 2385-2390
40. McGovern, S. L.; Helfand, B. T.; Feng, B.; Shoichet, B. K. A specific mechanism of nonspecific inhibition J. Med. Chem. 2003, 46, 4265-4272
41. Doak, A. K.; Wille, H.; Prusiner, S. B.; Shoichet, B. K. Colloid formation by Drugs in Simulated Intestinal Fluid J. Med. Chem. 2010, 53, 4259-4265
42. Coan, K. E.; Shoichet, B. K. Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors J. Am. Chem. Soc. 2008, 130, 9606-9612
43. Coan, K. E. D.; Ottl, J.; Klumpp, M. Non-stoichiometric inhibition in biochemical high-throughput screening Expert Opin. Drug Discovery 2011, 6, 405-417
44. Wang, J.; Matayoshi, E. Solubility at the Molecular Level: Development of a Critical Aggregation Concentration (CAC) Assay for Estimating Compound Monomer Solubility Pharm. Res. 2012, 29, 1745-1754
45. LaPlante, S. R.; Carson, R.; Gillard, J.; Aubry, N.; Coulombe, R.; Bordeleau, S.; Bonneau, P.; Little, M.; O'Meara, J.; Beaulieu, P. L. Compound Aggregation in Drug Discovery: Implementing a Practical NMR Assay for Medicinal Chemists J. Med. Chem. 2013, 56, 5142-5150
46. Coan, K. E.; Maltby, D. A.; Burlingame, A. L.; Shoichet, B. K. Promiscuous aggregate-based inhibitors promote enzyme unfolding J. Med. Chem. 2009, 52, 2067-2075
47. Owen, S. C.; Doak, A.; Wassam, P.; Shoichet, M. S.; Shoichet, B. K. Colloidal Aggregation Affects the Efficacy of Anticancer Drugs in Cell Culture ACS Chem. Biol. 2012, 7, 1429-1435
48. Frenkel, Y. V.; Clark, A. D., Jr.; Das, K.; Wang, Y.-H.; Lewi, P. J.; Janssen, P. A. J.; Arnold, E. Concentration and pH Dependent Aggregation of Hydrophobic Drug Molecules and Relevance to Oral Bioavailability J. Med. Chem. 2005, 48, 1974-1983
49. Frenkel, Y. V.; Gallicchio, E.; Das, K.; Levy, R. M.; Arnold, E. Molecular Dynamics Study of Non-nucleoside Reverse Transcriptase Inhibitor 4-[[4-[[4-[(E)-2-Cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile (TMC278/Rilpivirine) Aggregates: Correlation between Amphiphilic Properties of the Drug and Oral Bioavailability J. Med. Chem. 2009, 52, 5896-5905